**QUEEN'S
UNIVERSITY
BELFAST**

Intratumoral sterol-27-hydroxylase (CYP27A1) expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer

Khan, N. A., Stopsack, K., Allott, E. H., Gerke, T., Giovannucci, E. L., Mucci, L. A., & Kantoff, P. W. (2019). Intratumoral sterol-27-hydroxylase (CYP27A1) expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer. *Cancer Epidemiology Biomarkers & Prevention*, 28(6), 1052-1058. <https://doi.org/10.1158/1055-9965.EPI-18-1083>

Published in:
Cancer Epidemiology Biomarkers & Prevention

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights
Copyright 2019 AACR. This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Intratumoral sterol-27-hydroxylase (CYP27A1) expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer

Nabeela A. Khan,^{1*} Konrad H. Stopsack,^{1,2*} Emma H. Allott,^{2,3} Travis A. Gerke,^{2,4}
Edward L. Giovannucci,^{2,5,6} Lorelei A. Mucci,^{2,6} Philip W. Kantoff¹

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

² Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

³ University of North Carolina, Department of Nutrition, Chapel Hill, NC

⁴ Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL

⁵ Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA

⁶ Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA

* These authors contributed equally.

Correspondence: Phil or Konrad

Keywords: CYP27A1, 27-OH-cholesterol, prostate cancer, cholesterol, vitamin D

Prior presentation: Presented in part at the Annual Meeting of the American Association for Cancer Research, Chicago, IL, April 14–18, 2018

Word count: Abstract 251, Manuscript 3040 [with “Harvard”-style citations]

Funding: The Health Professionals Follow-up Study is supported by the National Institutes of Health (U01 CA167552). The Physicians' Health Study was supported by the National Institutes of Health (CA097193, CA34944, CA40360, HL26490, HL34595). The Department of Defense supported K.H.S. (W81XWH-18-1-0330) and P.W.K. (W81XWH-14-1-0515). This research was funded in part by the Dana-Farber/Harvard Cancer Center Specialized Programs of Research Excellence program in Prostate Cancer 5P50 CA090381 and the NIH/NCI Cancer Center Support Grants P30 CA008748 and P30 CA06516. K.H.S. and L.A.M. are Prostate Cancer Foundation Young Investigators.

Acknowledgments: We would like to thank the participants and staff of the Health Professionals Follow-up Study and the Physicians' Health Study for their valuable contributions. In particular, we would like to recognize the contributions of Liza Gazeeva, Siobhan Saint-Surin, Robert Sheahan, and Betsy Frost-Hawes. We would like to thank the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

Conflicts of interest: The authors declare no potential conflicts of interest.

Abstract

Background: Higher intratumoral cholesterol synthesis is associated with a worse prognosis in prostate cancer. The vitamin D-regulated enzyme sterol-27-hydroxylase (CYP27A1) converts cholesterol to 27-hydroxycholesterol, a potential endogenous selective estrogen receptor modulator (SERM). We hypothesized that low CYP27A1 expression is associated low vitamin D signaling, high cholesterol synthesis, and higher risk of lethal prostate cancer.

Methods: We studied 404 patients in the prospective prostate cancer cohorts within the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS). We quantified intratumoral CYP27A1 expression and proxies of cholesterol synthesis and vitamin D signaling using transcriptome profiling and assessed prediagnostic plasma 25-hydroxyvitamin D (25(OH)D, n = 132) and intratumoral vitamin D receptor protein expression (VDR, n = 300). Lethal disease was defined as prostate cancer mortality or metastases, in contrast to non-lethal disease without metastases after >8 years of follow-up since diagnosis.

Results: CYP27A1 expression was lower in tumors with higher Gleason grade and higher expression of the second rate-limiting enzyme of cholesterol synthesis, SQLE. We did not detect consistent associations between CYP27A1 and plasma 25(OH)D, CYP24A1, or intratumoral VDR expression. Lower CYP27A1 was associated with higher risk of lethal cancer in both cohorts (adjusted odds ratio for lowest vs. highest quartile of expression, 3.04; 95% CI, 1.46–6.33); this association was attenuated when additionally adjusting for Gleason grade and SQLE (odds ratio, 1.76; 95% CI, 0.75–4.17).

Conclusion: Low CYP27A1 expression is associated with higher cholesterol synthesis and a higher risk of lethal disease in prostate cancer. Whether the SERM-properties of 27-hydroxycholesterol underlie these associations requires further study.

Introduction

Prostate tissue has long been recognized to contain considerable amounts of cholesterol, particularly when undergoing carcinogenic transformation (Schaffner, 1981). More recently, several studies have suggested that higher serum cholesterol levels are associated with increased risk of advanced stage, higher-grade, or fatal prostate cancer (Batty *et al.*, 2011, Mondul *et al.*, 2011, Platz *et al.*, 2008), while others reported null associations (Jacobs *et al.*, 2012). Higher intratumoral synthesis of cholesterol, as assessed through expression of the second rate-limiting enzyme of cholesterol synthesis, squalene monooxygenase (*SQLE*), is associated with a higher risk of lethal prostate cancer (Stopsack *et al.*, 2016).

A key metabolite of cholesterol is 27-hydroxycholesterol. In preclinical breast cancer models, added 27-hydroxycholesterol stimulated tumor growth, acting partially as an endogenous selective estrogen receptor modulator (SERM) (Nelson *et al.*, 2013, Umetani *et al.*, 2007, Warner and Gustafsson, 2014). Intriguingly, high expression of the enzyme that synthesizes 27-hydroxycholesterol, 27-hydroxylase (*CYP27A1*), has been reported to be associated with higher tumor grade in breast cancer yet better prognosis (Kimbung *et al.*, 2017, Nelson *et al.*, 2013). In prostate cancer, a recent study reported *CYP27A1* expression to be strongly inversely related to Gleason grade (Alfaqih *et al.*, 2017). Moreover, *CYP27A1* catalyzes the 25-hydroxylation step of vitamin D, which might have a protective effect in various cancers including prostate cancer (Feldman *et al.*, 2014, Shui and Giovannucci, 2014).

We hypothesized that low *CYP27A1* expression, potentially resulting in cholesterol accumulation, occurs in prostate cancers that have higher expression of the cholesterol synthesis pathway. We also hypothesized that low *CYP27A1* expression is associated with low vitamin D signaling. To test these hypotheses, we conducted a cross-sectional analysis of two large, well characterized populations of patients with prostate cancer. In a longitudinal design, we tested our hypothesis that low *CYP27A1* would be associated with a higher risk of lethal prostate cancer over long-term follow-up.

Methods

Study populations

We studied patients who were diagnosed with prostate cancer during follow-up of two prospective cohort studies, the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS).

The HPFS enrolled 51,529 male health professionals, aged 40 to 75 years, in 1986 (Giovannucci *et al.*, 2007). Participants have been followed through biannual questionnaires since. The PHS enrolled 29,071 male physicians, aged ≥ 40 years, in 1982, initially for randomized-controlled trials of aspirin (Steering Committee of the Physicians' Health Study Research Group, 1989) and micronutrients (Christen *et al.*, 2000). Blood samples were collected from cancer-free participants in 1982 (PHS) and in 1993–95 (HPFS). Self-reported prostate cancer diagnoses in both cohorts are verified through review of medical records. Tissue from all patients included in this study also underwent centralized pathology review. Patients are followed prospectively for metastases and

prostate cancer-specific death (lethal cancer; with 98% completeness in HPFS and 99% in PHS for adjudication of death causes).

Within the prostate cancer biorepository from HPFS and PHS, we conducted a nested “extreme” case-control study, including of whole-transcriptome profiling of the tumor tissue, which oversampled patients with lethal outcome and those with available blood specimens from before cancer diagnosis (Sinnott *et al.*, 2017).

Participants provided written informed consent. The research was approved by the institutional review boards at Harvard T.H. Chan School of Public Health and Partners Healthcare.

Tumor profiling and plasma levels

For all patients included in this study, we retrieved tumor specimens from cancer diagnosis from the treating hospital. Expert genitourinary pathologists performed centralized histologic re-review, including Gleason grading (Stark (Rider) *et al.*, 2009), and selected high-density tumor areas (>80% tumor cell density). Transcriptome profiling included mRNA expressions of *CYP27A1*, *SQLE*, and *CYP24A1*. Tumor tissue and, if available, adjacent non-cancer prostate tissue, was measured on the Affymetrix GeneChip Human Gene 1.0 ST array (Gene Expression Omnibus: GSE62872), with post-processing as previously described (Penney *et al.*, 2016).

Plasma 25-hydroxy-vitamin D [25(OH)D] from blood samples before cancer diagnosis was measured as a part of a case-control study nested within HPFS. A radioimmunosorbent assay was used, as previously described (Shui *et al.*, 2012).

Vitamin D receptor (VDR) expression in the cytoplasm and membrane was stained via immunohistochemistry on tissue microarrays. Using a semiautomated quantitative image analysis system, the VDR score was generated as a combination of the relative area positively stained and the intensity of staining, as previously described (Hendrickson *et al.*, 2011). *TMPRSS2:ERG* status was determined using a genomically-validated ERG immunohistochemistry (Pettersson *et al.*, 2012).

Statistical analysis

Our analysis plan had two main parts. First, we assessed cross-sectionally how *CYP27A1* expression was associated with measures of vitamin D signaling and intratumoral cholesterol synthesis. Second, in a longitudinal analysis, we assessed the association between *CYP27A1* at cancer diagnosis and the risk of lethal disease over long-term follow-up. All tests were two-sided.

To assess the associations of 25(OH)D, VDR, *SQLE*, *CYP24A1*, ERG, and *CYP27A1*, we used linear regression. Between *CYP27A1* and *CYP24A1* expressions, we also calculated Pearson correlation coefficients *r*. Values for 25(OH)D were adjusted for season- and batch, as previously described (Shui *et al.*, 2012); VDR scores were adjusted for differences in mean values between tissue microarrays (Hendrickson *et al.*, 2011). We modeled the predictor in categories and inspected plots to assess for potential non-linear relationships, and we calculated tests for linear trend across quartiles by modeling the category medians (for 25(OH)D and VDR) or category indices (mRNA variables) as ordinal predictors. In a sensitivity analysis, we replaced *SQLE* as a proxy for cholesterol synthesis activity of the tumor by a summary score of all cholesterol synthesis genes (Stopsack *et*

et al., 2016). This summary score was the first principal component from principal components analysis of all cholesterol synthesis genes. Higher levels indicated higher expression of the cholesterol synthesis pathway, as 20 of the 21 cholesterol synthesis genes were positively loaded on this principal component.

To assess the association of *CYP27A1* expression (modeled in quartiles) and lethal disease, we used logistic regression to estimate odds ratios (OR) and 95% confidence intervals. Models were additionally adjusted for age (linear), year of diagnosis (categorical: pre-prostate specific antigen [PSA] era, 1982–1988; peri-PSA era, 1989–1993; PSA era, 1994–2005), smoking status (binary: current smoker vs. never/prior smoking), family history of prostate cancer in father or brothers (binary: yes/no), body mass index (categorical: <25, 25–30, >30 kg/m²), and hyperlipidemia (binary: self-report of hyperlipidemia by the health professionals vs. no such report). In separate models, we adjusted for Gleason grade (categorical: 5–6, 3+4, 4+3, 8, 9–10) and *SQLE* expression (categorical: quartiles). In an exploratory analysis, we assessed the association of *CYP27A1* within low and high strata of cholesterol synthesis activity defined by *SQLE* and the cholesterol signature. Given its strong association with lethal disease specifically in the highest quartile (Stopsack *et al.*, 2017), *SQLE* in the fourth quartile was considered high; the upper half of the signature was considered high.

Results

Study populations and tumor characteristics at cancer diagnosis

Baseline characteristics of 254 patients from HPFS and 150 patients from PHS are shown in Table 1. 59% of patients had pathologically organ-confined cancers (T1/T2 N0 M0), and 59% were diagnosed in the PSA screening era. 92% of tumor samples were from radical prostatectomy. Plasma concentrations of 25(OH)D before cancer diagnosis were available for a subset of 132 patients from HPFS. VDR protein expression had been quantified for 300 patients.

Notably, *CYP27A1* expression was lower in higher-grade, advanced stage, and ERG-positive cancers (Table 1). Compared to Gleason grade 5–6, tumors with Gleason grade 9–10 had on average 0.73 standard deviations (SD) lower *CYP27A1* expression (95% CI, 0.38 to 1.08 SD; $p_{\text{trend}} < 0.001$). ERG-positive tumors had 0.27 SD lower *CYP27A1* expression (95% CI, 0.06 to 0.47) than ERG-negative tumors.

Cross-sectional analysis: Vitamin D signaling, cholesterol synthesis, and CYP27A1 expression

We assessed the association of circulating and intratumoral indicators of vitamin D signaling and *CYP27A1* mRNA expression. Circulating plasma 25(OH)D was not associated with *CYP27A1*; the difference in *CYP27A1* expression between the lowest quartile of 25(OH)D and the highest quartile was 0.04 SD (95% CI, –0.55 to 0.46; $p_{\text{trend}} = 0.42$; Figure 1.A). *CYP27A1* expression was also not associated with VDR expression in the tumor; the difference in VDR expression score was 0.20 SD (95% CI, –0.25 to 0.66 SD) between the lowest and the highest quartile of *CYP27A1* ($p_{\text{trend}} = 0.09$; Figure 1.B). In contrast, we observed a weak positive correlation between *CYP27A1* and the expression of the VDR target gene *CYP24A1* ($r = 0.17$; 95% CI, 0.07 to 0.27; Figure 1.C).

To assess the association between intratumoral cholesterol synthesis and *CYP27A1*, we used the second rate-limiting enzyme of cholesterol synthesis, *SQLE*, and a score summarizing the

mRNA expression of all cholesterol synthesis enzymes as proxies. *CYP27A1* was lower in tumors with higher *SQLE* expression; the difference in *CYP27A1* between first and fourth quartile of *SQLE* was -0.42 SD (95% CI, -0.69 to -0.14 ; $p_{\text{trend}} = 0.002$ across quartiles of *SQLE*; Figure 1.D). Similar results were observed when we used the summary score instead of *SQLE* as a proxy for cholesterol synthesis in the tumor, observing a difference in *CYP27A1* between first and fourth quartile of the score of -0.49 SD (95% CI, -0.77 to -0.22 ; $p_{\text{trend}} = 0.001$).

In normal prostate tissue, we also did not observe associations between *CYP27A1* expression and plasma 25(OH)D and VDR expression (results not shown). In contrast to tumor tissue, *CYP27A1* expression and *CYP24A1* expression were not correlated in normal prostate tissue ($r = 0.03$; 95% CI, -0.11 to 0.17), and there was no statistically significant difference in *CYP27A1* expression between the lowest and highest quartiles of *SQLE* (difference, -0.15 SD; 95% CI, -0.54 to 0.25 ; $p_{\text{trend}} = 0.44$)

Longitudinal analysis: CYP27A1 and lethal disease

Patients were followed a median of 15.3 years for the development of metastases or death from prostate cancer (lethal disease). Lower intratumoral *CYP27A1* mRNA expression was associated with a higher risk of lethal disease over long-term follow-up in both cohorts (Table 2). In HPFS, patients with *CYP27A1* mRNA expression in the lowest quartile had a 2.64-fold higher risk of lethal disease (95% CI, 1.23 to 5.67), compared to patients with *CYP27A1* in the highest quartile. In PHS, the OR was 4.65 (95% CI, 0.92 to 23.5). Combining both cohorts and adjusting for additional baseline characteristics, the OR was 3.04 (95% CI, 1.46–6.33; $p_{\text{trend}} = 0.007$ across quartiles of *CYP27A1*). The association of *CYP27A1* and lethal disease remained significant but was attenuated somewhat when additionally adjusting for *SQLE* (OR for lowest vs. highest quartile of *CYP27A1*, 2.64; 95% CI, 1.24 to 5.62). Results were similar when adjusting for the summary score of cholesterol synthesis. Additional adjustment for Gleason grade considerably attenuated the association of *CYP27A1* and lethal disease (OR, 1.92; 95% CI, 0.83 to 4.46).

As expected, *CYP27A1* expression in tumor-adjacent normal prostate tissue was not associated with lethal disease (OR for lowest vs. highest quartile, 1.50; 95% CI, 0.66 to 3.44; $p_{\text{trend}} = 0.24$).

Finally, we assessed if the association of intratumoral *CYP27A1* with lethal disease differed within levels of cholesterol synthesis. The association between *CYP27A1* and lethal disease appeared to be slightly stronger in patients with low *SQLE* ($p_{\text{interaction}} = 0.17$). However, we did not observe a similar pattern when stratifying by the summary score of cholesterol synthesis (Table 2; $p_{\text{interaction}} = 0.63$).

Discussion

In this study, we assessed regulators of *CYP27A1*, which synthesizes 27-hydroxycholesterol from cholesterol, and its associations with long-term prognosis in patients with primary prostate cancer. We found *CYP27A1* expression to be low in tumors that had higher expression of cholesterol synthesis enzymes including *SQLE*. In contrast, we did not detect strong associations between several measures of vitamin D signaling and *CYP27A1*. Notably, low *CYP27A1* expression was

associated with a higher risk of lethal disease, beyond the elevated risk associated with higher expression of the cholesterol synthesis pathway. These findings advance our understanding of the complex role of cholesterol in prostate cancer and may help inform us about the role of *CYP27A1* in cancer more broadly.

We observed a strong inverse relationship between *CYP27A1* expression and two different measures of intratumoral cholesterol synthesis, the expression of the second rate-limiting enzyme *SQLE* as well as all enzymes constituting the cholesterol synthesis pathway. These observations suggest that in tumors with activated cholesterol synthesis, hydroxylation of cholesterol to 27-hydroxycholesterol is inhibited, perhaps in order to make cholesterol available for other purposes in rapidly dividing cells like cell membrane function. Concordantly, a preclinical study found the addition of 27-hydroxycholesterol to prostate cancer cell lines and xenografts attenuated their growth and decreased the expression of *SREBP2*, the main transcription factor regulating cholesterol synthesis (Alfaqih *et al.*, 2017). However, discordant experimental results, partially using the same cell line, have been reported as well (Raza *et al.*, 2017).

Despite assessing multiple proxies of vitamin D signaling activity, including plasma 25(OH)D concentrations, VDR protein expression in tumor tissue, and mRNA expression of the VDR target gene *CYP24A1*, we did not find consistent evidence that showed *CYP27A1* to be strongly related to vitamin D signaling. However, these measures may not have fully captured an effect of exogenous vitamin D on *CYP27A1* expression, particularly if vitamin D is 25-hydroxylated directly within prostate cells without changing plasma 25(OH)D concentrations. This 25-hydroxylation step of vitamin D has indeed been observed in a non-tumor prostate cell line, in which vitamin D also induced *CYP27A1* expression (Tokar and Webber, 2005). However, the 25-hydroxylase function of *CYP27A1* may not be physiologically relevant in peripheral tissues as the prostate, but rather fulfilled by the microsomal 25-hydroxylase *CYP2R1* (Jones *et al.*, 2014). Ultimately, our observations lend no additional support to *CYP27A1* expression in prostate cancer tissue being tightly controlled by vitamin D signaling. We also assessed if *TMPRSS2:ERG* status was associated with *CYP27A1* expression. Bidirectional influences between vitamin D signaling, including VDR and *CYP24A1*, and *TMPRSS2:ERG* have been reported in prostate cancer cell lines (Kim *et al.*, 2014, Washington and Weigel, 2010), and we previously observed that ERG-positive tumors have higher VDR expression (Hendrickson *et al.*, 2011). In the present study, we only observed a modest association between ERG status and *CYP27A1* expression, and *CYP24A1* expression did not differ by ERG status (data not shown).

In breast cancer, several studies found *CYP27A1* expression to be higher in high-grade compared to low-grade cancers (Kimbung *et al.*, 2017, Nelson *et al.*, 2013). In prostate cancer, a relatively strong, inverse relationship with Gleason grade has been reported previously (Alfaqih *et al.*, 2017) and was confirmed by our data. *CYP27A1* expression has also been reported to be lower in castration-resistant cancer tissue compared to tissue from castration-sensitive tumors (Tamura *et al.*, 2007). How strongly *CYP27A1* expression would be associated with risk of clinically relevant outcomes such as metastases or cancer death was unknown. Our data indicated an appropriately three-fold higher risk of lethal cancer among the 25% patients with the lowest *CYP27A1* expression (first quartile), compared to the 25% with the highest expression (fourth quartile; Table 2). Given the tight association of *CYP27A1* and Gleason grade, it is unsurprising that these estimates were

attenuated considerably when additionally adjusting for Gleason grade. Our results are supported by a previous study that included a larger set of prostate cancer patients from HPFS and found single nucleotide polymorphisms within *CYP27A1* to be associated with the risk of lethal disease (Shui *et al.*, 2012); however, we do not know if and how these single nucleotide polymorphisms influence *CYP27A1* mRNA expression.

While *CYP27A1* does not appear to be well suited as a prognostic marker, our results are informative for mechanistic studies. In particular, it has been suggested that a large proportion of the association of *CYP27A1* expression and prognosis in breast cancer is due to SERM effects of 27-hydroxycholesterol (Nelson, 2017). These associations were also most pronounced in premenopausal patients with estrogen receptor-positive tumors (Kimbung *et al.*, 2017). Upregulated cholesterol synthesis and production of 27-hydroxycholesterol in estrogen receptor-positive breast cancer under antiestrogen therapy has been suggested as a mechanism of therapy resistance (Nguyen *et al.*, 2015, Simigdala *et al.*, 2016). In our study, we found a moderately strong association of *CYP27A1* with lethal disease, which might suggest that at least in prostate cancer, *CYP27A1* and 27-hydroxycholesterol would act to some extent through non-SERM mechanisms. Alternatively, 27-hydroxycholesterol might be important to consider as a potential ligand when assessing the role of estrogen receptor beta, which is expressed in at least a subset of prostate tumors (Nanni *et al.*, 2009).

We did not find that the association of *CYP27A1* expression and lethal disease differed across levels of cholesterol synthesis enzyme expression (Table 2). This could mean that *CYP27A1*, or tumor features associated with it, drive cancer progression in addition to cholesterol synthesis. Importantly, absence of a statistical interaction between cholesterol synthesis and *CYP27A1* on a multiplicative scale should not be interpreted as evidence against biological interaction between them, but rather as the opposite (Greenland *et al.*, 2008).

It should be noted that we measured mRNA levels of *CYP27A1* and not protein expression. In an ecologic analysis of a small number of breast tissue samples before and after atorvastatin exposure, *CYP27A1* protein appeared to show changes in the opposite direction than *CYP27A1* mRNA (Kimbung *et al.*, 2017). In contrast, in prostate cancer tissue, *CYP27A1* protein expression was lost in the tumor epithelium in contrast to normal glands, consistent with observations on the mRNA level (Alfaqih *et al.*, 2017). However, this comparison was also ecological, and we are unaware of a study directly comparing mRNA and protein levels within the same patients. An additional limitation of our study is that only a relatively small subset of patients had prediagnostic plasma samples, which may have contributed to the null results for plasma 25(OH)D.

In summary, we found low intratumoral *CYP27A1* mRNA expression to be associated with higher markers of intratumoral cholesterol synthesis, higher Gleason grade, and a higher risk of lethal disease over long-term follow-up. We did not find strong associations of *CYP27A1* and circulating 25(OH)D or with two measures of intratumoral vitamin D signaling. Future studies should consider estrogen receptor expression when evaluating *CYP27A1* in prostate cancer and should ideally attempt to directly measure intratumoral or circulating 27-hydroxycholesterol. Interestingly, serum 27-hydroxycholesterol concentrations were decreased by atorvastatin treatment and by vitamin D supplementation in two small-scale clinical trials among patients with breast cancer (Going

et al., 2017, Kimbung *et al.*, 2017). It remains to be seen how such interventions might affect intratumoral cholesterol and 27-hydroxycholesterol levels as well as clinical outcomes for patients with prostate cancer.

References

- Alfaqih MA, Nelson ER, Liu W, Safi R, Jasper JS, Macias E, et al. CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. *Cancer Res* 2017;77(7):1662-73.
- Batty GD, Kivimaki M, Clarke R, Davey Smith G, Shipley MJ. Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. *Cancer Causes Control* 2011;22(2):311-8.
- Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. *Ann Epidemiol* 2000;10(2):125-34.
- Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. *Nat Rev Cancer* 2014;14(5):342-57.
- Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. *Int J Cancer* 2007;121(7):1571-8.
- Going CC, Alexandrova L, Lau K, Yeh CY, Feldman D, Pitteri SJ. Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial. *Breast Cancer Res Treat* 2017.
- Greenland S, Lash TL, Rothman KJ. Concepts of Interaction. In: Rothman KJ, Greenland S, Lash TL, editors. *Modern Epidemiology*. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
- Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. *BMJ* 2016;352:i1981.
- Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. *J Clin Oncol* 2011;29(17):2378-85.
- Jacobs EJ, Stevens VL, Newton CC, Gapstur SM. Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Cancer Causes Control* 2012;23(8):1289-96.
- Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. *J Lipid Res* 2014;55(1):13-31.
- Kim JS, Roberts JM, Bingman WE, 3rd, Shao L, Wang J, Ittmann MM, et al. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. *Endocrinology* 2014;155(9):3262-73.
- Kimbung S, Chang CY, Bendahl PO, Dubois L, Thompson JW, McDonnell DP, et al. Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer. *Endocr Relat Cancer* 2017;24(7):339-49.
- Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. *Cancer Causes Control* 2011;22(11):1545-52.
- Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, et al. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. *J Clin Invest* 2009;119(5):1093-108.
- Nelson ER. The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer. *Mol Cell Endocrinol* 2017.
- Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. *Science* 2013;342(6162):1094-8.
- Nguyen VT, Barozzi I, Faronato M, Lombardo Y, Steel JH, Patel N, et al. Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. *Nat Commun* 2015;6:10044.
- Penney KL, Pettersson A, Shui IM, Graff RE, Kraft P, Lis RT, et al. Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes. *Cancer Epidemiol Biomarkers Prev* 2016;25(5):745-9.
- Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2012;21(9):1497-509.

- Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. *Int J Cancer* 2008;123(7):1693-8.
- Raza S, Meyer M, Goodyear C, Hammer KDP, Guo B, Ghribi O. The cholesterol metabolite 27-hydroxycholesterol stimulates cell proliferation via ERbeta in prostate cancer cells. *Cancer Cell Int* 2017;17:52.
- Schaffner CP. Prostatic cholesterol metabolism: regulation and alteration. *Prog Clin Biol Res* 1981;75A:279-324.
- Shui I, Giovannucci E. Vitamin D status and cancer incidence and mortality. *Adv Exp Med Biol* 2014;810:33-51.
- Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. *J Natl Cancer Inst* 2012;104(9):690-9.
- Simigdala N, Gao Q, Pancholi S, Roberg-Larsen H, Zvelebil M, Ribas R, et al. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. *Breast Cancer Res* 2016;18(1):58.
- Sinnott JA, Peisch SF, Tyekucheva S, Gerke T, Lis R, Rider JR, et al. Prognostic Utility of a New mRNA Expression Signature of Gleason Score. *Clin Cancer Res* 2017;23(1):81-7.
- Stark (Rider) JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? *J Clin Oncol* 2009;27(21):3459-64.
- Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med* 1989;321(3):129-35.
- Stopsack KH, Gerke TA, Andren O, Andersson SO, Giovannucci EL, Mucci LA, et al. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. *Carcinogenesis* 2017;38(8):806-11.
- Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, et al. Cholesterol Metabolism and Prostate Cancer Lethality. *Cancer Res* 2016;76(16):4785-90.
- Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. *Cancer Res* 2007;67(11):5117-25.
- Tokar EJ, Webber MM. Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. *Clin Exp Metastasis* 2005;22(3):265-73.
- Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. *Nat Med* 2007;13(10):1185-92.
- Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and breast cancer. *N Engl J Med* 2014;370(6):572-3.
- Washington MN, Weigel NL. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. *Endocrinology* 2010;151(4):1409-17.

Table 1. Characteristics of prostate cancer patients from the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS), by *CYP27A1* mRNA expression in tumor tissue. Within each quartile, absolute counts (out of 101 patients) closely approximate percentages.

	Quartile of <i>CYP27A1</i> mRNA expression in tumor tissue			
	1 st (lowest)	2 nd	3 rd	4 th (highest)
<i>n</i>	101	101	101	101
Age at diagnosis, median (range)	67 (49–80)	66 (47–80)	66 (50–81)	65 (52–77)
Year of diagnosis, <i>n</i>				
Before 1993	31	47	43	37
After 1993	69	54	57	63
Gleason grade, <i>n</i>				
5–6	10	11	13	23
7 (3+4)	24	36	38	41
7 (4+3)	34	24	24	20
8	12	17	9	5
9–10	21	13	17	12
Stage, <i>n</i>				
T1/T2	50	56	65	68
T3	38	37	29	28
T4/N1/M1	13	8	7	5
Prostate-specific antigen [ng/dl], <i>n</i>				
<4	6	9	9	9
4–10	50	41	49	58
>10	27	32	31	20
Missing	18	19	12	14
Current smoking at diagnosis, <i>n</i>	9	6	2	7
Body mass index [kg/m ²], <i>n</i>				
<25	54	53	45	41
25–30	35	43	54	52
>30	12	5	2	8
Hypercholesterolemia, <i>n</i>	32	29	30	24
Statin use at diagnosis, <i>n</i>	9	11	10	13
Plasma 25(OH)D [ng/ml], median (interquartile range)	25 (21–32)	24 (19–29)	27 (22–35)	26 (19–28)
<i>TMPRSS2:ERG</i> status, <i>n</i> ^a				
ERG-positive	53	47	47	35
ERG-negative	39	47	41	56

^a Based on immunohistochemistry for ERG protein. Missing for 39 patients in total.

Table 2. *CYP27A1* mRNA expression in tumor tissue and lethal prostate cancer.

	Quartile of <i>CYP27A1</i> mRNA expression in tumor tissue				p_{trend}^a
	1st (lowest)	2 nd	3 rd	4 th (highest)	
HPFS					
Cases: lethal, non-lethal, <i>n</i>	28, 34	20, 45	20, 44	15, 48	
OR (95% CI), ^b unadjusted	2.64 (1.23–5.67)	1.42 (0.65–3.11)	1.45 (0.66–3.19)	1 (reference)	0.018
PHS					
Cases: Lethal, non-lethal, <i>n</i>	8, 31	10, 26	10, 27	2, ^c 36	
OR (95% CI), ^b unadjusted	4.65 (0.92–23.5)	6.92 (1.40–34.3)	6.67 (1.35–33.9)	1 (reference)	0.12
Combined HPFS and PHS,					
OR (95% CI) ^b					
Model 1: Unadjusted	2.73 (1.41–5.30)	2.09 (1.06–4.10)	2.09 (1.06–4.10)	1 (reference)	0.005
Model 2: Adjusted ^d	3.04 (1.46–6.33)	2.17 (1.04–4.53)	2.40 (1.15–5.00)	1 (reference)	0.007
Model 3: Model 2 + <i>SQLE</i> ^e	2.64 (1.24–5.62)	2.17 (1.03–4.58)	2.30 (1.08–4.88)	1 (reference)	0.022
Model 4: Model 2 + chol. score ^e	2.86 (1.35–6.05)	2.02 (0.95–4.29)	2.40 (1.14–5.05)	1 (reference)	0.015
Model 5: Model 3 + Gleason	1.76 (0.75–4.17)	1.84 (0.77–4.41)	2.05 (0.87–4.86)	1 (reference)	0.31
By cholesterol score,^f					^g
OR (95% CI) ^b					
Score < median	2.95 (1.12–7.81)	1.89 (0.67–5.41)	1.77 (0.65–4.79)	1 (reference)	0.032
Score ≥ median	2.22 (0.89–5.57)	1.79 (0.72–4.48)	2.18 (0.85–5.60)	1 (reference)	0.17

^a Test for linear trend across quartiles, modelled as ordinal indices

^b Odds ratios for lethal disease with 95% confidence intervals

^c Because of the few events in the reference category for PHS (*n* = 2), the odds ratios for PHS alone should be interpreted cautiously in light of probable sparse-data bias (Greenland *et al.*, 2016).

^d Adjusted for age (linear), year of diagnosis (categorical), smoking status at cancer diagnosis (binary), body mass index (categorical), high serum cholesterol (binary)

^e *SQLE* and summary score of expression levels for all cholesterol synthesis genes were in quartiles

^f HPFS and PHS combined; unadjusted estimates within levels of the cholesterol summary score

^g Test for multiplicative interaction between *CYP27A1* quartile indices (ordinal) and cholesterol summary score (binary)

Figure Labels

Figure 1. Regulation of *CYP27A1* mRNA expression in tumor issue. **A.** Plasma 25(OH)D and *CYP27A1* mRNA. **B.** *CYP27A1* mRNA and VDR expression in tumor tissue (in dimensionless units). **C.** *CYP27A1* and *CYP24A1* mRNA. **D.** *SQLE* mRNA and *CYP27A1* mRNA. All units of mRNA expression are standard deviations.

Figure 2. Causal diagram highlighting the complex interplay between cholesterol synthesis, vitamin D signaling, and *CYP27A1* in prostate cancer. Note that the graph should be considered incomplete from causal inference standpoint (i.e., it does not list all confounders necessary to estimate causal effects).
[appropriate for readership?]